

Manthena V S Varma

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6960885/publications.pdf>

Version: 2024-02-01

47
papers

2,270
citations

201674

27
h-index

214800

47
g-index

48
all docs

48
docs citations

48
times ranked

1645
citing authors

#	ARTICLE	IF	CITATIONS
1	Physicochemical Space for Optimum Oral Bioavailability: Contribution of Human Intestinal Absorption and First-Pass Elimination. <i>Journal of Medicinal Chemistry</i> , 2010, 53, 1098-1108.	6.4	247
2	Physicochemical Determinants of Human Renal Clearance. <i>Journal of Medicinal Chemistry</i> , 2009, 52, 4844-4852.	6.4	174
3	Physiologically Based Modeling of Pravastatin Transporter-Mediated Hepatobiliary Disposition and Drug-Drug Interactions. <i>Pharmaceutical Research</i> , 2012, 29, 2860-2873.	3.5	122
4	pH-Sensitive Interaction of HMG-CoA Reductase Inhibitors (Statins) with Organic Anion Transporting Polypeptide 2B1. <i>Molecular Pharmaceutics</i> , 2011, 8, 1303-1313.	4.6	97
5	Mechanistic Modeling to Predict the Transporter- and Enzyme-Mediated Drug-Drug Interactions of Repaglinide. <i>Pharmaceutical Research</i> , 2013, 30, 1188-1199.	3.5	96
6	Quantitative Prediction of Human Renal Clearance and Drug-Drug Interactions of Organic Anion Transporter Substrates Using In Vitro Transport Data: A Relative Activity Factor Approach. <i>Drug Metabolism and Disposition</i> , 2017, 45, 409-417.	3.3	95
7	Prediction of Pharmacokinetics and Drug-Drug Interactions When Hepatic Transporters are Involved. <i>Clinical Pharmacokinetics</i> , 2014, 53, 659-678.	3.5	92
8	Renal clearance in drug discovery and development: molecular descriptors, drug transporters and disease state. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2010, 6, 939-952.	3.3	82
9	Physicochemical Property Space of Hepatobiliary Transport and Computational Models for Predicting Rat Biliary Excretion. <i>Drug Metabolism and Disposition</i> , 2012, 40, 1527-1537.	3.3	66
10	Quantitative Rationalization of Gemfibrozil Drug Interactions: Consideration of Transporters-Enzyme Interplay and the Role of Circulating Metabolite Gemfibrozil 1-O-Glucuronide. <i>Drug Metabolism and Disposition</i> , 2015, 43, 1108-1118.	3.3	65
11	Model-based approaches to predict drug-drug interactions associated with hepatic uptake transporters: preclinical, clinical and beyond. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2013, 9, 459-472.	3.3	63
12	Quantitative Prediction of Transporter- and Enzyme-Mediated Clinical Drug-Drug Interactions of Organic Anion-Transporting Polypeptide 1B1 Substrates Using a Mechanistic Net-Effect Model. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2014, 351, 214-223.	2.5	61
13	Hepatobiliary Clearance Prediction: Species Scaling From Monkey, Dog, and Rat, and In Vitro-In Vivo Extrapolation of Sandwich-Cultured Human Hepatocytes Using 17 Drugs. <i>Journal of Pharmaceutical Sciences</i> , 2017, 106, 2795-2804.	3.3	59
14	Dealing with the complex drug-drug interactions: Towards mechanistic models. <i>Biopharmaceutics and Drug Disposition</i> , 2015, 36, 71-92.	1.9	58
15	Quantitative Contribution of Six Major Transporters to the Hepatic Uptake of Drugs: SLC-Phenotyping Using Primary Human Hepatocytes. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2019, 370, 72-83.	2.5	58
16	Quantitative Prediction of Repaglinide-Rifampicin Complex Drug Interactions Using Dynamic and Static Mechanistic Models: Delineating Differential CYP3A4 Induction and OATP1B1 Inhibition Potential of Rifampicin. <i>Drug Metabolism and Disposition</i> , 2013, 41, 966-974.	3.3	55
17	Quantitative Proteomics and Mechanistic Modeling of Transporter-Mediated Disposition in Nonalcoholic Fatty Liver Disease. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 107, 1128-1137.	4.7	51
18	Mechanism-Based Pharmacokinetic Modeling to Evaluate Transporter-Enzyme Interplay in Drug Interactions and Pharmacogenetics of Glyburide. <i>AAPS Journal</i> , 2014, 16, 736-748.	4.4	47

#	ARTICLE	IF	CITATIONS
19	Organic Anion Transporter 2-Mediated Hepatic Uptake Contributes to the Clearance of High-Permeability-Low-Molecular-Weight Acid and Zwitterion Drugs: Evaluation Using 25 Drugs. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2018, 367, 322-334.	2.5	44
20	Transporter-Mediated Hepatic Uptake Plays an Important Role in the Pharmacokinetics and Drug-Drug Interactions of Montelukast. <i>Clinical Pharmacology and Therapeutics</i> , 2017, 101, 406-415.	4.7	43
21	Role of Hepatic Organic Anion Transporter 2 in the Pharmacokinetics of R- and S-Warfarin: In Vitro Studies and Mechanistic Evaluation. <i>Molecular Pharmaceutics</i> , 2018, 15, 1284-1295.	4.6	41
22	Reliable Rate Measurements for Active and Passive Hepatic Uptake Using Plated Human Hepatocytes. <i>AAPS Journal</i> , 2017, 19, 787-796.	4.4	39
23	Navigating Transporter Sciences in Pharmacokinetics Characterization Using the Extended Clearance Classification System. <i>Drug Metabolism and Disposition</i> , 2018, 46, 729-739.	3.3	37
24	Extended Clearance Classification System (ECCS) informed approach for evaluating investigational drugs as substrates of drug transporters. <i>Clinical Pharmacology and Therapeutics</i> , 2017, 102, 33-36.	4.7	36
25	Induction of Human Intestinal and Hepatic Organic Anion Transporting Polypeptides: Where Is the Evidence for Its Relevance in Drug-Drug Interactions?. <i>Drug Metabolism and Disposition</i> , 2020, 48, 205-216.	3.3	36
26	Organic Anion Transporter 2 Mediates Hepatic Uptake of Tolbutamide, a CYP2C9 Probe Drug. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2018, 364, 390-398.	2.5	35
27	Simultaneous Assessment of Transporter-Mediated Drug-Drug Interactions Using a Probe Drug Cocktail in Cynomolgus Monkey. <i>Drug Metabolism and Disposition</i> , 2018, 46, 1179-1189.	3.3	34
28	Comparison of Proteomic Quantification Approaches for Hepatic Drug Transporters: Multiplexed Global Quantitation Correlates with Targeted Proteomic Quantitation. <i>Drug Metabolism and Disposition</i> , 2018, 46, 692-696.	3.3	25
29	Drug-Drug Interactions Involving Renal OCT2/MATE Transporters: Clinical Risk Assessment May Require Endogenous Biomarker-Informed Approach. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 110, 855-859.	4.7	23
30	Molecular properties associated with transporter-mediated drug disposition. <i>Advanced Drug Delivery Reviews</i> , 2017, 116, 92-99.	13.7	22
31	Nicotinic acid transport into human liver involves organic anion transporter 2 (SLC22A7). <i>Biochemical Pharmacology</i> , 2020, 174, 113829.	4.4	22
32	Quantitative prediction of breast cancer resistant protein mediated drug-drug interactions using physiologically-based pharmacokinetic modeling. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2021, 10, 1018-1031.	2.5	22
33	Quantification of Hepatic Organic Anion Transport Proteins OAT2 and OAT7 in Human Liver Tissue and Primary Hepatocytes. <i>Molecular Pharmaceutics</i> , 2018, 15, 3227-3235.	4.6	21
34	Effect of Hepatic Organic Anion-Transporting Polypeptide 1B Inhibition and Chronic Kidney Disease on the Pharmacokinetics of a Liver-Targeted Glucokinase Activator: A Model-Based Evaluation. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 106, 792-802.	4.7	21
35	Clinical Implications of Altered Drug Transporter Abundance/Function and PBPK Modeling in Specific Populations: An ITC Perspective. <i>Clinical Pharmacology and Therapeutics</i> , 2022, 112, 501-526.	4.7	21
36	Quantitative Prediction of Drug-Drug Interactions Involving Inhibitory Metabolites in Drug Development: How Can Physiologically Based Pharmacokinetic Modeling Help?. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2016, 5, 505-515.	2.5	19

#	ARTICLE	IF	CITATIONS
37	Optimizing the Benefit/Risk of Acetyl-CoA Carboxylase Inhibitors through Liver Targeting. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 10879-10896.	6.4	19
38	Mechanistic Evaluation of the Complex Drug-Drug Interactions of Maraviroc: Contribution of Cytochrome P450 3A, P-Glycoprotein and Organic Anion Transporting Polypeptide 1B1. <i>Drug Metabolism and Disposition</i> , 2019, 47, 493-503.	3.3	17
39	Effect of Human Plasma on Hepatic Uptake of Organic Anion-Transporting Polypeptide 1B Substrates: Studies Using Transfected Cells and Primary Human Hepatocytes. <i>Drug Metabolism and Disposition</i> , 2021, 49, 72-83.	3.3	17
40	In Vitro-to-In Vivo Extrapolation of Transporter-Mediated Renal Clearance: Relative Expression Factor Versus Relative Activity Factor Approach. <i>Drug Metabolism and Disposition</i> , 2021, 49, 470-478.	3.3	17
41	Predicting the Human Hepatic Clearance of Acidic and Zwitterionic Drugs. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 11831-11844.	6.4	14
42	Transporter-enzyme interplay and the hepatic drug clearance: what have we learned so far?. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2020, 16, 387-401.	3.3	14
43	Clopidogrel as a Perpetrator of Drug-Drug Interactions: A Challenge for Quantitative Predictions?. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 105, 1295-1299.	4.7	12
44	Organic Anion-Transporting Polypeptide 1B1/1B3-Mediated Hepatic Uptake Determines the Pharmacokinetics of Large Lipophilic Acids: In Vitro-In Vivo Evaluation in Cynomolgus Monkey. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2021, 377, 169-180.	2.5	12
45	Transporter-Mediated Disposition, Clinical Pharmacokinetics and Cholestatic Potential of Glyburide and Its Primary Active Metabolites. <i>Drug Metabolism and Disposition</i> , 2017, 45, 737-747.	3.3	8
46	Cytochrome-P450-Mediated Drug-Drug Interactions of Substrate Drugs: Assessing Clinical Risk Based on Molecular Properties and an Extended Clearance Classification System. <i>Molecular Pharmaceutics</i> , 2020, 17, 3024-3032.	4.6	8
47	Response to the Comment on the Article "Physiologically Based Modeling of Pravastatin Transporter-Mediated Hepatobiliary Disposition and Drug-Drug Interactions". <i>Pharmaceutical Research</i> , 2013, 30, 1469-1470.	3.5	3